Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 13:03, 2 December 2010 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:Wi). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Idraparinux

Clinical data
Routes of administration	Subcutaneous
ATC code	none
Legal status
Legal status	Investigational
Pharmacokinetic data
Elimination half-life	80-130 hours
Identifiers
IUPAC name Nonasodium (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6- [(2R,3S,4S,5R,6R)-2-carboxylato- 4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5- disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl] oxyoxan-3-yl]oxy-4,5-disulfonatooxy- 2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy- 3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy- 6-(sulfonatooxymethyl)oxan-2-yl]oxyoxane- 2-carboxylate
CAS Number	149920-56-9
PubChem CID	3083444
ChemSpider	2340656
Chemical and physical data
Formula	C38H55Na9O49S7
Molar mass	1727.17683 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES CO1(O((1OC)OC)O2(((O2C(=O))O3(O((3OS(=O)(=O))OS(=O)(=O))O4(((O4C(=O))O5(O((5OS(=O)(=O))OS(=O)(=O))OC)COS(=O)(=O))OC)OC)COS(=O)(=O))OC)OC)COS(=O)(=O).........
InChI InChI=1S/C38H64O49S7.9Na/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54;;;;;;;;;/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63);;;;;;;;;/q;9*+1/p-9/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-;;;;;;;;;/m1........./s1 Key:MVPQUSQUURLQKF-MCPDASDXSA-E
(verify)

Idraparinux sodium is an anticoagulant medication in development by Sanofi-Aventis.

It has a similar chemical structure and the same method of action as fondaparinux, but with an elimination half-life about five to six times longer (an increase from fondaparinux's 17 hours to approximately 80 hours), which means that the drug should only need to be injected once a week.

As of July 2007, it has completed the Phase III clinical trial AMADEUS.

Method of action

Idraparinux selectively blocks coagulation factor Xa.

See Heparin: Mechanism of anticoagulant action for a comparison of the mechanism of heparin, low-molecular-weight heparins, fondaparinux and idraparinux.

References

1. Bousser MG, Bouthier J, Büller HR; et al. (2008). "Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial". Lancet. 371 (9609): 315–21. doi:10.1016/S0140-6736(08)60168-3. PMID 18294998. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
2. Buller HR, Cohen AT, Davidson B; et al. (2007). "Idraparinux versus standard therapy for venous thromboembolic disease". N. Engl. J. Med. 357 (11): 1094–104. doi:10.1056/NEJMoa064247. PMID 17855670. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

• Drugs not assigned an ATC code
• Oligosaccharides
• Heparins